Table 1 Patient demographic characteristics at entry. (P-values are from t-tests comparing those who took each drug to those who did not.)
All Subjects | Subjects with follow up | Exposed to ZDV* | Exposed to ddI† | |
|---|---|---|---|---|
N | 33 | 23 | 19 | 7 |
Age in years: Mean (Range) | 35.3 (23 – 51) | 35.5 (23 – 51) | 36.2 (23 – 51) (p = .27) | 35.4 (25 – 51) (p = .97) |
Male, N (%) | 31 (94%) | 21 (91%) | 18 (95%) (p = .20) | 6 (86%) (p = .53) |
Race, N (%) | ||||
White Black Hispanic Asian | 24 (73%) 3 (9%) 1 (3%) 5 (15%) | 16(70%) 2 (9%) 1 (4%) 4 (17%) | 14 (74%) 1 (5%) 0 (0%) 4 (21%) (p = .062) | 6 (86%) 0 (0%) 1 (14%) 0 (0%) (p = .15) |
CD4+ T-cells/ul Mean (Range) | 483 (213 – 1130) | 481 (213 – 960) | 472 (213 – 960) (p = .64) | 714 (444 – 960) (p < .0001) |
Plasma HIV RNA‡ 1000 copies per/ml Mean (Range) | 102 (0.1 – 670) (N = 31) | 75 (0.1 – 505) (N = 22) | 87 (0.1 – 505) (p = .69) | 2.8 (0.1 – 8.0) (p = .0006) |
Low Frequency PTA§in dB Mean (Range) | 11 (0 – 40) (N = 32) | 12 (0 – 40) | 14 (1 – 40) (p = .41) | 16 (0.5 – 40) (p = .40) |
High Frequency PTA in dB Mean (Range) | 20 (0.8 – 51) (N = 32) | 22 (1.7 – 51) | 22 (2 – 51) (p = .98) | 23 (3 – 50) (p = .64) |